SOS Ras/Rho guanine nucleotide exchange factor 2Genealiases: NS9 · SOS-2
Q-omics provides the consensus-scored SOS2 profile across patient tissues and cancer cell-line models. SOS2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SOS2 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, SOS2 RNA expression shows 21,068 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where SOS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOS2 survival associations across molecular data types. SOS2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOS2 RNA expression–survival associations across cancer types. High SOS2 expression shows unfavorable associations in MESO and DLBC, but favorable associations in KIRC, UCS, SKCM and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SOS2 RNA expression.
This table summarizes SOS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SOS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOS2 shows lower tumor expression in COAD, THCA, KIRC and BRCA and higher tumor expression in LIHC and HNSC. The COAD box plot shows higher SOS2 RNA expression in normal versus tumor tissue (log2 FC = −1.215, t-test p < 0.001).
This table shows molecular features associated with SOS2 in patient tissues and cancer cell lines. In patient samples, SOS2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SOS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
